Alnylam Pharmaceuticals: Takeaways from ALNY’s 6400 bleeding disorder roundtable

Research evidence excerpt

Alnylam Pharmaceuticals: Takeaways from ALNY’s 6400 bleeding disorder roundtable

Accessible version

Alnylam Pharmaceuticals

Takeaways from ALNY’s 6400 bleeding

disorder roundtable

Maintain Rating: BUY | PO: 460.00 USD | Price: 291.37 USD

6400 has broad potential in bleeding disorders 29 June 2026

ALNY highlighted ALN-6400, plasminogen (PLG)-targeted RNAi, as one of the key long- Equity

term growth drivers in the pipeline. 6400 has a differentiated mechanism of action by

Tazeen Ahmad

stabilizing clots via fibrinolysis inhibition supporting potential to broadly address Research Analyst

bleeding disorders and provide a safer alternative to existing antifibrinolytics with no BofAS tazeen.ahmad@bofa.com

meaningful thrombotic risk. They reiterated HHT as a leading indication and announced

Daniel Giraldo

VWD as the second indication for the program. They noted HHT and VWD are the two Research Analyst

most common inherited bleeding disorders worldwide and have high unmet need BofAS daniel.giraldoperez@bofa.com

representing a multi-billion-dollar opportunity. We are encouraged by 6400’s potential Jeremiah Lorentz

in several bleeding disorders and novel MoA as we await further clinical validation. 6400 Research Analyst

is currently part of our pipeline value. We maintain our Buy with $460 PO. BofASjeremiah.lorentz@bofa.com

ALNY estimates ~70K HHT patients in the US WesleyResearchYonAnalyst

HHT is a genetic disorder resulting in abnormal blood vessel formation leading to BofASwesley.yon@bofa.com

recurrent and often severe nose bleeds as well as potential organ complications and Amy Qian

anemia. ALNY highlighted these patients have preserved clot formation making Research Analyst

fibrinolysis inhibition a good approach.